|1.||Hofmann, Stefan G: 19 articles (07/2015 - 03/2006)|
|2.||Otto, Michael W: 16 articles (07/2015 - 03/2006)|
|3.||Smits, Jasper A J: 11 articles (08/2015 - 03/2006)|
|4.||Pollack, Mark H: 11 articles (07/2015 - 03/2006)|
|5.||Rosenfield, David: 8 articles (12/2015 - 02/2013)|
|6.||Javitt, Daniel C: 7 articles (12/2012 - 03/2002)|
|7.||Goff, Donald C: 6 articles (03/2014 - 07/2002)|
|8.||Heresco-Levy, Uriel: 6 articles (10/2007 - 03/2002)|
|9.||Simon, Naomi M: 5 articles (12/2013 - 03/2006)|
|10.||Meuret, Alicia E: 5 articles (12/2013 - 03/2006)|
|1.||Anxiety Disorders (Anxiety Disorder)
04/01/2012 - "D-Cycloserine appears to be an effective augmentation agent that enhances the effects of behavioral therapy in the treatment of anxiety disorders. "
01/01/2014 - "In recent years, several studies have demonstrated efficacy of d-cycloserine (DCS) enhanced exposure therapy across anxiety disorders. "
12/01/2013 - "The aim of the current study was to identify individual characteristics that (a) predict symptom improvement with group cognitive behavioral therapy (CBT) for social anxiety disorder (SAD; i.e., prognostic variables) or (b) moderate the effects of d-cycloserine (DCS) versus placebo augmentation of CBT for SAD (i.e., prescriptive variables). "
10/01/2013 - "The evidence for the efficacy of D-cycloserine (DCS) for augmenting cognitive behavioral therapy (CBT) for anxiety disorders has been mixed. "
04/01/2012 - "To determine the efficacy of D-cycloserine augmentation of behavioral therapy for the treatment of anxiety disorders. "
|2.||Schizophrenia (Dementia Praecox)
12/01/2008 - "Daily dosing with d-cycloserine has inconsistently improved negative symptoms in schizophrenia patients, whereas intermittent dosing significantly facilitated exposure-based therapy in two studies of patients with phobic anxiety. "
03/01/2014 - "d-Cycloserine (DCS) has been shown to enhance memory and, in a previous trial, once-weekly DCS improved negative symptoms in schizophrenia subjects. "
12/01/2008 - "Once-weekly D-cycloserine effects on negative symptoms and cognition in schizophrenia: an exploratory study."
08/01/1999 - "Further placebo-controlled studies with lower dosages of D-cycloserine, preferably in drug-free patients, are necessary to evaluate if D-cycloserine is of use for the treatment of patients with schizophrenia."
01/01/1999 - "Forty-seven patients with schizophrenia meeting criteria for deficit syndrome were randomized to D-cycloserine, 50 mg/d (n=23) or placebo (n=24) added to their conventional neuroleptic for an 8-week, double-blind trial. "
|3.||Post-Traumatic Stress Disorders (PTSD)
08/01/2015 - "Extinction learning as a moderator of d-cycloserine efficacy for enhancing exposure therapy in posttraumatic stress disorder."
09/01/2012 - "A randomized placebo-controlled trial of D-cycloserine and exposure therapy for posttraumatic stress disorder."
06/01/2012 - "A randomized placebo-controlled trial of D-cycloserine to enhance exposure therapy for posttraumatic stress disorder."
12/01/2002 - "Pilot-controlled trial of D-cycloserine for the treatment of post-traumatic stress disorder."
07/01/2014 - "D-cycloserine can help as an adjunctive treatment to alleviate numbing and avoidance in combat-related chronic PTSD."
10/18/1956 - "[Cycloserine, a new antibiotic, effective against tuberculosis]."
01/01/2011 - "D-Cycloserine (DCS), an analog of D-Ala and a prototype Ddl inhibitor, has shown promise for the treatment of tuberculosis. "
01/01/1970 - "In vitro studies of the possibility of using cycloserine as a tuberculostatic in combination with intermittent therapy of tuberculosis."
01/01/1963 - "[Pathohistological study of the healing processes in experimental tuberculosis under the influence of cycloserine]."
01/01/1958 - "[Clinical studies of a recent anti-tuberculosis antibiotic: cycloserine]."
05/01/1989 - "As seen in this table, clinical efficacy of cycloserine was expected in the treatment of infections caused by Mycobacterium kansasii, M. "
05/01/1989 - "Evaluation of cycloserine as a drug in the treatment of infections caused by nontuberculous mycobacteria was made from in-vitro studies, in which Mycobacterium tuberculosis strains were used as the standard of the evaluation. "
01/01/2010 - "Comparing cycloserine with sulphadimidine, no significant differences in symptomatic, persistent, or recurrent infections were noted. "
05/01/1989 - "[Evaluation of cycloserine in the treatment of infections caused by nontuberculous mycobacteria viewed from in vitro experiments]."
10/01/1965 - "The evaluation of seromycin in pyogenic infection of the urinary tract."
|2.||Glycine (Aminoacetic Acid)
|5.||Serotonin (5 Hydroxytryptamine)
|8.||Antipsychotic Agents (Antipsychotics)
|1.||Drug Therapy (Chemotherapy)
|3.||Investigational Therapies (Experimental Therapy)
|4.||Highly Active Antiretroviral Therapy (HAART)